Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its interim results for the half year ended
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has told DirectorsTalk that the abstract and poster relating to
Northland Capital partners view of Evgen Pharma plc LON:EVG: In line with our expectations, Evgen has received regulatory approval to commence its second Phase 2 trial, a study that will
Dr Stephen Franklin, CEO of Evgen Pharma LON:EVG, commented: “Many therapies used in cancer ultimately fail as patients develop resistance – one hypothesis is that this resistance is driven by
Evgen Pharma’s Stephen Franklin discusses their final results for year ending 31st March 2016 in this exclusive interview with DirectorsTalk
Evgen Pharma plc (LON:EVG) CEO Stephen Franklin caught up with DirectorsTalk to discuss the company’s maiden results, the two phase II trials and when we can expect them to report
Northland Capital partners view on Evgen Pharma LON:EVG: Evgen Pharma’s maiden Final Results for the year ended 31 March 2016 were ahead of our expectations. The company is prudently deploying
Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma LON:EVG said: “I am very pleased with the significant progress the Company has made since joining AIM in October last year. We
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
